# Clinical Outcomes Using Coronary CT Angiography and FFR<sub>CT</sub> Guided Management of Stable Chest Pain Patients


Bjarne L. Nørgaard, Christian J. Terkelsen, Ole N. Mathiassen, Erik L. Grove, Hans Erik Bøtker, Erik Parner, Jonathon Leipsic, Flemming H. Steffensen, Anders H. Riis, Kamilla Pedersen, Evald H. Christiansen, Michael Mæng, Lars R. Krusell, Steen D. Kristensen, Ashkan Eftekhari, Lars Jakobsen, Jesper M. Jensen



**Aarhus University Hospital, Aarhus, Denmark** 

# **Background**

Coronary CT Angiography:



- Can accurately exclude the presence of CAD¹
- Prognostic implications<sup>2</sup>
- Cannot determine the physiologic significance of lesions<sup>3</sup>

Non-invasive strategies are needed to identify those patients with CAD who may benefit from cardiac catherization and those who do not require further testing

<sup>1</sup>Abdulla J et al, EHJ 2007; <sup>2</sup>Nielsen LH et al, EHJ 2017; <sup>2</sup>Xie JX et al, iJACC 2018; <sup>3</sup>Meijboom WB et al, JACC 2008; <sup>3</sup>Norgaard BL et al, JACC 2014

# **Background**

CTA derived fractional flow reserve (FFR<sub>CT</sub>):



- Have shown promise in guiding downstream management of patients with CAD<sup>2</sup>
- One-year outcomes of FFR<sub>CT</sub> guided care in a clinical trial setting was favorable<sup>2</sup>

Longer term clinical outcome data in patients undergoing CTA testing with FFR<sub>CT</sub> guidance in day-to-day practice is sparse

# Overall purpose of the study

 To assess the safety and clinical outcomes of utilizing a diagnostic strategy of first-line coronary CTA with selective FFR<sub>CT</sub> testing in real world symptomatic patients with suspected stable CAD

# Study design

 Single-center, observational all-comer study of symptomatic patients undergoing nonemergent coronary CTA for suspected CAD with selective FFR<sub>CT</sub> testing between May 2014 and December 2016

- Data sources
  - The Western Denmark Cardiac Computed Tomography Registry<sup>1</sup>
    - Patient demographics, CTA results
  - The Danish National Patient Registry<sup>2</sup>
    - Discharge diagnoses, test and procedures for all in and outpatient encounters
  - The Danish Civil Registration system<sup>3</sup>
    - Data on mortality

#### **Patients**

- All Aarhus University Hospital patients with new onset chest pain and suspected CAD who had non-emergent coronary CTA performed from May 2014 to December 2016
  - Coronary CTA is the first-line test in such patients
  - CTA acquisition was performed according to societal guidelines<sup>1</sup>
    - Exclusion from CTA: Contrast allergy, pregnancy, scenarios where a diagnostic image quality cannot be expected (combination of e.g. obesity, arrhytmia, and severe calcification)

# Post-test management, Coronary CTA


	Test outcome	Post-test management recommendations
<b>Coronary CTA</b>		
Diagnostic conclusive	High-risk anatomy	ICA
	Intermediate-risk anatomy	FFR <sub>CT</sub>
	Low-risk anatomy	No further testing
Diagnostic inconclusive	-	MPI, or ICA

Optimal medical treatmet was recommended in all patients with CAD ICA =invasive coronary angiography, MPI =myocardial perfusion imaging

# Post-test management, FFR<sub>CT</sub>

	Test outcome	Post-test management recommendations
FFR <sub>CT</sub>		
Diagnostic conclusive	Negative, all values >0.80	OMT, no additional testing
	<b>Positive</b> , one or more values ≤0.80	
	-Lesion-specific ischemia	OMT or ICA
	-Distal vessel positivity	OMT
Diagnostic inconclusive	-	MPI, or ICA

ICA =invasive coronary angiography, MPI =myocardial perfusion imaging, OMT =optimal medical treatment



# **Endpoint, Follow-up, and Study aims**

- Endpoint: Composite of all-cause death, non-fatal myocardial infarction, hospitalization for unstable angina, and unplanned revascularization
- **Follow-up**: Median 24 (interquartile range, 16-32; range, 8-41) months. No patients were lost to follow-up


• **Primary aim**: The cumulative incidence of the combined endpoint in patients with FFR<sub>CT</sub>>0.80, and no additional testing compared to patients with no or minimal (stenosis severity <30%) CAD

# **Endpoint, Follow-up, and Study aims**

- Endpoint: Composite of all-cause death, non-fatal myocardial infarction, hospitalization for unstable angina, and unplanned revascularization
- **Follow-up**: Median 24 (interquartile range, 16-32; range, 8-41) months. No patients were lost to follow-up
- **Primary aim**: The cumulative incidence of the combined endpoint in patients with FFR<sub>CT</sub>>0.80, and no additional testing compared to patients with no or minimal (stenosis severity <30%) CAD
- **Secondary aim**: The cumulative incidence of the combined endpoint in patients with  $FFR_{CT} \le 0.80$  (OMT or ICA), compared to patients with CTA stenosis < 30%



#### **Results: Patients Flow-chart**





### **Results: Baseline characteristics**

	CTA stenosis <30%	CTA stenosis ≥30%		P-value (FFR <sub>CT</sub> >0.80	
	OMT (n =2540)	FFR <sub>CT</sub> >0.80, OMT (n=410)	FFR <sub>CT</sub> ≤0.80, OMT or ICA (n=267)	versus FFR <sub>CT</sub> ≤0.80 group)	
Age, yrs, mean	56	60	62	0.006	
Male, %	43	55	65	0.02	
Diabetes mellitus,%	6	9	14	0.16	
Hypertension,%	30	40	50	0.005	
Updated D-F score, mean %	31	43	47	0.01	




# **Results: Anatomical characteristics**

	FFR <sub>CT</sub> >0.80, OMT (n=410)	FFR <sub>CT</sub> ≤0.80, OMT or ICA (n=267)	P-value
Maximum CTA stenosis			
30-49%	25%	9%	<0.001
50-69%	65%	59%	0.10
≥70%	10%	32%	<0.001
Vessels with stenosis ≥50%			<0.001
1	63%	56%	
2	10%	27%	
3	1%	7%	
Mean Agatston score	164	456	<0.001



\*All-cause death, non-fatal myocardial MI, hospitalization for unstable angina, unplanned revascularization




Number at risk

CTA stenosis<30%	2540	2187	1226	28
FFR <sub>CT</sub> >0.80	410	366	187	49



\*All-cause death, non-fatal myocardial MI, hospitalization for unstable angina, unplanned revascularization






	CTA stenosis <30%	CTA stenosis ≥30%			P-value
	OMT (n=2540)	FFR <sub>CT</sub> >0.80, OMT (n=410)	FFR <sub>CT</sub> ≤0.80, OMT (n=112)	FFR <sub>CT</sub> ≤0.80, ICA (n=155)	
Composite end-point	2.8 (1.4-4.9)	3.9 (2.0-6.9)	9.4 (3.0-20.0)	6.6. (2.5-13.4)	0.07
All-cause death	2.3 (1.0-4.4)	1.4	1.5	2.8	0.97
Non-tatal MI	0.3 (0.1-0.6)	0.3	8.0 (2.2-18.6)	1.3	<0.001
Hospitalization for UA	0.1	1.7	0.9	2.5	0.01
Unplanned revascularization	0.4 (0.2-0.8)	1.0	8.8 (2.2-18.6)	0	<0.01



\*All-cause death, non-fatal myocardial MI, hospitalization for unstable angina, unplanned revascularization





# **Summary**

• In a real-world setting of symptomatic patients without known CAD, the presence of intermediate range CTA stenosis and FFR<sub>CT</sub> >0.80 was associated with favorable clinical outcomes similar to patients with no or minimal evidence of CAD

• Risk of an unfavorable outcome was increased (driven by a higher incidence of non-fatal MI) in patients with  $FFR_{CT} \le 0.80$ , who were not referred to ICA



#### Conclusion

• In a real-world clinical practice, a diagnostic strategy of first-line coronary CTA in symptomatic patients suspected of CAD, and  $FFR_{CT}$  testing in those with intermediate range lesions is effective in differentiating patients who do not require further diagnostic testing or intervention ( $FFR_{CT} > 0.80$ ) from higher risk patients ( $FFR_{CT} \leq 0.80$ ) in whom further testing with ICA and possibly intervention may be needed



# Thank you!